From: Diagnostic value of circN4BP2L2 in type I and type II epithelial ovarian cancer
Type II EOC cohort | Benign cohort | Normal cohort | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | Median (range) | Median (range) | ROC AUC (95% CI) | Sen | Spe | P-value | Median (range) | ROC AUC (95% CI) | Sen | Spe | P-value |
CircN4BP2L2 | 19 (1–84) | 82 (1–367) | 0.88 (0.84–0.91) | 93% | 71% | < 0.01* | 82 (11–439) | 0.91 (0.88–0.94) | 80% | 87% | < 0.01* |
 Early-stage a | 24 (1–74) |  | 0.85 (0.79–0.92) | 88% | 67% | < 0.01* |  | 0.89 (0.83–0.95) | 83% | 77% | < 0.01* |
 Late-stage a | 19 (2–84) |  | 0.88 (0.84–0.92) | 94% | 69% | < 0.01* |  | 0.92 (0.89–0.95) | 83% | 87% | < 0.01* |
CA125 | 233 (18–5801) | 48 (13–373) | 0.72 (0.65–0.79) | 72% | 32% | < 0.01* | 29 (4–69) | 0.84 (0.79–0.89) | 72% | 58% | < 0.01* |
 Early-stage a | 30 (18–560) |  | 0.46 (0.31–0.60) | 46% | 32% | 0.49 |  | 0.68 (0.55–0.80) | 46% | 58% | < 0.01* |
 Late-stage a | 398 (22–5801) |  | 0.79 (0.72–0.86) | 79% | 32% | < 0.01* |  | 0.89 (0.84–0.94) | 79% | 58% | < 0.01* |
HE4 | 79 (32–438) | 46 (12–237) | 0.79 (0.73–0.84) | 75% | 76% | < 0.01* | 44 (7–235) | 0.78 (073–0.84) | 75% | 82% | < 0.01* |
 Early-stage a | 88 (34–231) |  | 0.77 (0.68–0.87) | 71% | 76% | < 0.01* |  | 0.75 (0.65–0.85) | 71% | 82% | < 0.01* |
 Late-stage a | 78 (32–438) |  | 0.79 (0.74–0.85) | 77% | 76% | < 0.01* |  | 0.79 (0.73–0.85) | 77% | 82% | < 0.01* |